About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Jun 3, 2019 9:39 am | eHealth, Other Services, Physician Medical Groups, Private Equity
Nearly halfway into 2019, and PE firms are showing no signs of slowing as they swarm the healthcare industry. So far this year, there have been 71 deals with a private equity firm as the buyer, or roughly 11% of the total deals announced. That’s roughly the same... Read More »
by Dylan Sammut | Jun 3, 2019 9:32 am | Laboratories, MRI & Dialysis
Lumos Diagnostics, a subsidiary of Planet Innovation, announced this week it acquired RPS Diagnostics for an undisclosed price. RPS develops, manufactures and markets rapid, point-of-care diagnostic tests for a variety of infectious diseases and inflammatory... Read More »
by Dylan Sammut | May 31, 2019 9:45 am | Healthcare Market Updates
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online... Read More »
by Dylan Sammut | May 28, 2019 10:31 am | eHealth
Slowly but surely, WELL Health Technologies Corp. (TSX.V: WELL) is building its own digital health platform. The Canadian healthcare operator announced it acquired OSCARprn for $876,000. Financial details include $619,500 upfront and $256,500 via 373,906 shares in the... Read More »
by Dylan Sammut | May 28, 2019 10:28 am | Biotechnology, Pharmaceuticals
Merck & Co., Inc. (NYSE: MRK) has been busy this year. After securing a licensing deal with Cocrystal (NASDAQ: COCP) for proprietary influenza A/B antiviral agents in January, the company found two biotechnology start-ups to bolster its cancer treatment... Read More »